Femasys lands $30M private placement, with up to $60M more tied to warrants

What's the deal? Femasys, an Atlanta-based biomedical company developing fertility and non-surgical permanent birth control products, has raised $30 million in a private placement led by new institutional investor Nantahala Capital ManagementDealroom has a profile for this one. Try Dealroom →, with participation from additional healthcare-focused funds and members of Femasys' management team.

The mechanics. Investors are buying common shares and pre-funded warrants at $3.20, alongside warrants exercisable at $2.95. If all warrants are exercised for cash, Femasys could receive up to $60 million more, although some are contingent on revenue and share-price milestones. The private placement is expected to close around 10 August 2026.

What it means. Femasys said the financing will strengthen its balance sheet as it expands its fertility portfolio and advances the FemBloc clinical and regulatory programme.

Read more: GlobeNewswire

Image credit: NavyMedicine